IMPDH2 Is an Intracellular Target of the Cyclophilin A and Sanglifehrin A Complex
Overview
Cell Biology
Molecular Biology
Affiliations
Natural products have demonstrated utility in the clinic and can also act as probes to understand complex cellular pathways. Sanglifehrin A (SFA) is a mixed polyketide and non-ribosomal peptide synthase natural product with sub-nano-molar affinity for its receptor cyclophilin A (PPIA). It has been shown to behave in vitro as an immune suppressant. Here, we identify inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) as an intracellular target of the PPIA-SFA binary complex. The formation of this ternary complex does not inhibit the enzymatic activity of IMPDH2. Rather, ternary complex formation modulates cell growth through interaction with the cystathionine-β-synthase (CBS) domain of IMPDH2. We further demonstrate that the SFA complex is highly isoform selective for IMPDH2 (versus IMPDH1). This work reveals a role for the CBS domains of IMPDH2 in cellular proliferation, suggesting a more complex role than previously suspected for IMPDH2 in T cell activation and proliferation.
Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV.
Newton L, Gathmann C, Ridewood S, Smith R, Wijaya A, Hornsby T Nat Commun. 2025; 16(1):1484.
PMID: 39929804 PMC: 11811207. DOI: 10.1038/s41467-025-56317-8.
Discovery of fully synthetic FKBP12-mTOR molecular glues.
Deutscher R, Meyners C, Repity M, Sugiarto W, Kolos J, Maciel E Chem Sci. 2025; 16(10):4256-4263.
PMID: 39916884 PMC: 11796051. DOI: 10.1039/d4sc06917j.
Dreizler J, Meyners C, Hausch F ACS Med Chem Lett. 2024; 15(11):2012-2018.
PMID: 39563809 PMC: 11571008. DOI: 10.1021/acsmedchemlett.4c00427.
Integrative Proteomics-Metabolomics of In Vitro Degeneration of Cardiovascular Cell Lines.
Yang S, Nan B, Shen H Appl Biochem Biotechnol. 2024; 197(1):216-240.
PMID: 39110328 DOI: 10.1007/s12010-024-05004-3.
Sanglifehrin A mitigates multiorgan fibrosis by targeting the collagen chaperone cyclophilin B.
Flaxman H, Chrysovergi M, Han H, Kabir F, Lister R, Chang C JCI Insight. 2024; 9(15).
PMID: 38900587 PMC: 11383833. DOI: 10.1172/jci.insight.171162.